ライフサイエンスコーパス: uricase

1 or, and pegloticase, a pegylated recombinant uricase.

2 a previous phase I trial of subcutaneous PEG-uricase.

3 ro upon binding uric acid, the substrate for uricase.

4 s antagonized by uric acid, the substrate of uricase.

5 fective and less immunogenic than unmodified uricase.

6 cid elimination is facilitated by the enzyme uricase.

7 ress its own expression as well as that of a uricase, a repression that is alleviated both in vivo an

8 Plasma uricase activity (pUox), the plasma urate concentration

9 of hucR and uricase transcript and increased uricase activity under conditions of excess uric acid fu

10 mans and great apes, which have lost hepatic uricase activity, leading to uniquely high serum uric ac

11 osed mice, the powerful inhibitory effect of uricase administration on allergic sensitization is medi

12 e oxidative end product of uric acid (UA) by uricase, an efficient and sensitive approach for uric ac

13 The enzymes uricase and ascorbate oxidase were used to remove uric a

14 system resulting from enzymatic reaction of uricase and HRP (horseradish peroxidase), which is invol

15 e system demonstrated sufficient activity of uricase and HRP at a ratio of 5U:5U and pH 7.0.

16 by binding a shared promoter region between uricase and HucR genes.

17 s well as urate-lowering therapies including uricase and inhibitors of renal urate transporter protei

18 summarizes the evidence regarding available uricases and those in the pipeline, their debulking effe

19 n shown to repress expression of a predicted uricase, and DNA-binding by HucR is antagonized by uric

20 Exogenic uricases are an exciting therapeutic option for patients

21 Uricases are being used to treat uncontrolled gout, and

22 oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trials.

23 eses that our ancestral primates inactivated uricase as a mechanism to increase triglyceride producti

24 modified recombinant mammalian uricases (PEG-uricase) as a potential therapy for gout and uric acid n

25 nalysis in comparison to clinically approved uricase assay indicated the high accuracy of the present

26 Single infusions of PEG-uricase (at doses ranging from 0.5 mg to 12 mg) were adm

27 models to understand the history of primate uricases by resurrecting ancestral mammalian intermediat

28 iguously that the archetypical cofactor-free uricase catalyzes uric acid degradation via a C5(S)-(hyd

29 e hyperuricemia induced by the inhibition of uricase, caused a robust mobilization of EPCs, whereas a

30 PEG-uricase could provide an effective therapy for uric acid

31 Uricases could become a leading choice in severe and dif

32 The studies reveal that the uricase/CuO/Pt/glass bio-electrode exhibits good lineari

33 ioelectrocatalytic oxidation of uric acid by uricase/CuO/Pt/glass electrode was studied without any e

34 lyses of this bioelectrode revealed that the uricase/CZTS/ITO/glass electrode exhibits good linearity

35 Ablation of the microbiota in uricase-deficient mice causes severe hyperuricemia, and

36 Uricase-deficient mice develop uric acid nephropathy, wi

37 e uric acid/creatinine ratio in the urine of uricase-deficient mice ranges from 10 to >30; on a weigh

38 Treatment of uricase-deficient mice with PEG-uricase markedly reduced

39 tes and normalized serum uric acid levels in uricase-deficient mice.

40 urate because we no longer have a functional uricase enzyme capable of oxidizing this highly insolubl

41 605), pegadricase, an immunogenic, pegylated uricase enzyme derived from Candida utilis, is assessed

42 e deposited using dip coating technique, and uricase enzyme have been immobilized onto CZTS films usi

43 The uricase enzyme significantly enhances plasmonic sensors

44 ensor employs the covalent immobilization of uricase enzyme using 1-Ethyl-3-(3-dimethylaminopropyl)ca

45 weat UA electrochemical biosensor based on a uricase-enzyme electrode and sweat wicking hydrogel.

46 ors, a nonxanthine oxidase inhibitor and the uricase enzymes have been developed adding to our armame

47 Infusing 4-12 mg of PEG-uricase every 2-4 weeks should maintain the pUAc well be

48 ponsive branch of the MarR family, regulates uricase expression in Deinococcus radiodurans by binding

49 Uricase expression is confirmed in both hepatocyte monol

50 ted recombinant mammalian urate oxidase (PEG-uricase) for the treatment of severe gout.

51 to the silencing or pseudogenization of the uricase gene in ancestral apes.

52 m uric acid due to missense mutations in the uricase gene.

53 occurred even when the enzymatic activity of uricase had been inactivated.

54 12 mM, indicate that the immobilized enzyme (uricase) has enhanced affinity towards its analyte (uric

55 Resurrected proteins reveal that ancestral uricases have steadily decreased in activity since the l

56 etection system consisting of combination of uricase/HRP-CdS quantum dots (QDs) for the determination

57 Availability, cost and uricase immunogenicity have limited their use.

58 lts from studies of pegloticase, a pegylated uricase in development, and we summarise data for severa

59 without APA, as well as serum levels of PEG-uricase in humans.

60 maging of radiolabeled PEG-liposomes and PEG-uricase in mice with and without APA, as well as serum l

61 Retention of uricase in most mammals and its loss in humans and some

62 protein concentrations equivalent to that of uricase inhibited NO2-promoted allergic airway disease.

63 ce exposed to NO2 and that administration of uricase inhibited the development of OVA-driven allergic

64 of tolerogenic nanoparticles with pegylated uricase inhibited the formation of ADAs in mice and non-

65 mentally increasing uric acid levels using a uricase inhibitor causes systemic hypertension in animal

66 (induced by continuous 2-wk treatment with a uricase inhibitor oxonic acid), EPC mobilization was blu

67 hyperuricemia in normal rats induced by the uricase inhibitor, oxonic acid (OA), results in hyperten

68 Finally, pharmacokinetics of an ancient uricase injected in rodents suggest that our integrated

69 PR technology to insert functional ancestral uricase into the genome of human liver cells to address

70 However, human uricase is a pseudogene, having been inactivated early i

71 Uricase is also highly expressed in mouse but not human

72 The presence of uricase is also shown to prevent an increase in triglyce

73 Uricase is an enzyme involved in purine catabolism and i

74 Curiously, uricase is not functional in some organisms despite its

75 dimensional imaging technique was applied to uricase knockout mice to demonstrate the method for the

76 Treatment of uricase-deficient mice with PEG-uricase markedly reduced urate levels and, when initiate

77 Uricase modified with a comprehensive zwitterionic polyc

78 The enzyme (uricase)-modified screen printed electrode system has be

79 IgG antibodies to PEG-uricase, mostly IgG2 and specific for PEG, developed in

80 The uricase mutation in the Miocene likely provided a surviv

81 PK behavior was unchanged, and neither anti-uricase nor anti-PCB antibodies were detected after thre

82 Here, working with resurrected ancestral uricases obtained from early hominids, we show that thei

83 ylene glycol)-modified recombinant mammalian uricases (PEG-uricase) as a potential therapy for gout a

84 lumen, and removal of this endogenous UA by uricase prevented type 2 immune responses.

85 increases in the abundance of Gram-negative uricase-producing pathobionts (Escherichia and Shigella)

86 tionary history by crystallizing a mammalian uricase protein.

87 t (and in opposing orientation) to the human uricase pseudogene.

88 epG2 liver cells to test one hypothesis that uricase pseudogenization allowed ancient frugivorous ape

89 3 A resolution structure of the hypothetical uricase regulator (HucR) from Deinococcus radiodurans R1

90 Hypothetical uricase regulator (HucR), which belongs to the ligand-re

91 rans-encoded MarR homolog HucR (hypothetical uricase regulator) and identified residues responsible f

92 , uricase was itself immunogenic, inducing a uricase-specific adaptive immune response that occurred

93 ImmTOR inhibits the development of uricase-specific ADAs in a dose-dependent manner, thus e

94 ntergenic region between hucR and a putative uricase suggests a mechanism of simultaneous co-repressi

95 x was linearly related to the IV dose of PEG-uricase, the area under the curve (AUC) value increased

96 evels than most mammals due to a mutation in uricase, the enzyme involved in uric acid degradation in

97 Uricase, the enzyme that catalyzes conversion of uric ac

98 acid excretion (lesinurad), and recombinant uricase to directly catabolize urate (pegloticase).

99 ific response was not due to the capacity of uricase to inhibit the early steps of OVA uptake or proc

100 The use of modified uricases to rapidly reduce serum urate concentrations in

101 electrocatalytic activity to the immobilized uricase towards the oxidation of analyte (uric acid) and

102 the enhanced affinity of immobilized enzyme (uricase) towards uric acid.

103 Enhanced levels in vivo of hucR and uricase transcript and increased uricase activity under

104 In species other than humans, uricase (urate oxidase) converts urate to allantoin, whi

105 Uricase (Urc) is an oxidoreductase enzyme of both genera

106 The substrate of uricase, uric acid, is an efficient antagonist of DNA bi

107 d in vitro and hyperuricemic geese, a native uricase via extracorporeal delivery was active in the di

108 PEG-uricase was far more effective and less immunogenic than

109 However, uricase was itself immunogenic, inducing a uricase-speci

110 ene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need.

111 events and the IgG antibody response to PEG-uricase were followed up for 35 days.

112 bility, efficacy, and tolerability of IV PEG-uricase were greater than the bioavailability, efficacy,

113 Further, ancient and modern uricases were stably transfected into HepG2 liver cells

114 as determined by blocking the hepatic enzyme uricase with oxonic acid (CSA-OA).